A UT Southwestern neurology expert and the CEO of GenrAb discuss neuro-immunology and finding antibodies that can help with neuronal damage

blonca9
Oct 30, 2024
1 min read

UTSW's Dr. Ben Greenberg discusses how neuro-immunology is making inroads for conditions like MS, ALS, and alzheimer's. GenrAb CEO Larry Tiffany provides an update on the company's lead antibody program.

Brought to you by

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

A UT Southwestern neurology expert and the CEO of GenrAb discuss neuro-immunology and finding antibodies that can help with neuronal damage

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight